GlassScriptPhysician profile
John J Looney
NPI 1003848532
$10,154.45
in general payments reported to CMS, 2019-2025
35 companies · $2,352 in 2025
The $2,352 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $129 · 2021: $879 · 2022: $1,162 · 2023: $2,364 · 2024: $2,791 · 2025: $2,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,506.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,735.12 | 2019-2025 | |
| Lilly USA, LLC | $1,314.87 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $1,151.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,113.25 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,043.56 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.84 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $366.16 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $272.18 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Exact Sciences Corporation | $206.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $167.89 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $162.82 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $157.49 | 2024-2025 | Rexulti |
| Dexcom, INC. | $131.08 | 2024-2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $130.95 | 2021 | |
| Glaxosmithkline, LLC. | $104.69 | 2019-2023 | Trelegy Ellipta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.20 | 2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $55.31 | 2021 | |
| Amarin Pharma, INC. | $53.27 | 2019-2020 | |
| Medtronic, INC. | $53.07 | 2024 | Minimed 780g |
| Ardelyx, INC. | $51.79 | 2024-2025 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $51.51 | 2022 | |
| Bausch Health US, LLC | $41.96 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.62 | 2021 | |
| Allergan, INC. | $26.67 | 2022 | |
| Dynavax Technologies Corporation | $25.88 | 2024 | Heplisav-B |
| Shield Therapeutics INC | $24.80 | 2024 | |
| Heartflow, INC. | $24.55 | 2024 | |
| Alkermes, INC. | $22.80 | 2025 | Aristada, Lybalvi |
| Becton, Dickinson and Company | $21.34 | 2025 | Bd Onclarity |
| Xeris Pharmaceuticals, INC. | $20.27 | 2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $17.24 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.81 | 2019 | |
| Esperion Therapeutics, INC. | $15.78 | 2023 | Nexletol |
| Idorsia Pharmaceuticals US INC | $15.26 | 2023 | Quviviq |
| Amgen INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Looney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.